Aaron Richterman, MD Profile picture
Sep 23, 2020 44 tweets 18 min read Read on X
Yesterday @EricMeyerowitz and I presented insights from new COVID19 papers published over the last month at the HOPE conference. Posting slides and video if interested

Video: hopeconference.net/conferences/fi…
Slide deck at end of thread


@HarvardCFAR @RMKGandhi
Agenda
What are the lessons (and unresolved questions) about hospital acquired infection
It became apparent during early Chinese epidemic that hospitals were important sites of transmission, >40% infections hospital acquired in Chinese case series

Illustrative example of major outbreak in S Africa stemming from single introduction:

krisp.org.za/manuscripts/St…
Patients/HCW rightly became scared, and we saw major and concerning decreases in healthcare utilization for urgent/emergent medical issues. E.g. new report showing marked decrease in patients with TB (#1 infectious killer worldwide) presenting for care
doi.org/10.3201/eid261…
However, at the same time, we began to see indirect evidence for high efficacy of relatively simple intervention => universal masking. Population-level study from Duke:

cambridge.org/core/journals/…
This nice new study from UAB illustrates the massive reduction in exposures with implementation of universal masking

academic.oup.com/cid/advance-ar…
Contact tracing study of patients exposed to HCW with infection show very low rates of infection in universal masking. Only 1 definitive infection out of 253 exposures during a 30 minute unmasked outpatient appointment.

pubmed.ncbi.nlm.nih.gov/32856692/
Complementary study showing nosocomial infection was extremely rare during the surge in Boston in universal masking era

jamanetwork.com/journals/jaman…
But how do we square these findings with ongoing reports of HCW making up large numbers of cases worldwide?

washingtonpost.com/world/2020/09/…
To explore this, we will go through this very interesting paper published in Lancet Public health, study of voluntary mobile app use including 2 million community members and 100k front-line hcw

doi.org/10.1016/S2468-…
They used multivariable models to find positive test highly associated with being a HCW, even after attempting to adjust for the much greater likelihood of having a test as a HCW (although much attenuated)
So, how do we explain all of these findings? The short answer is I don’t think we exactly know yet, but here are some proposed considerations.

What we really need is a detailed contact tracing study of healthcare worker infections in the universal masking era.
Lesson 1
Lesson 2
Lesson 3 - MOST critical point IMO. We need to understand residual outbreaks in the universal masking setting. Unmasked in work rooms or cafeterias = major culprit so far, we MUST support HCW to be able to work safely rather than pointing fingers (people gotta eat!!)
Next topic
For this we will be going through a few pieces of this fascinating paper, an almost forensic phylogenetic analysis providing lessons from the early global spread of CoV-2

science.sciencemag.org/content/early/…
They address two hypotheses in this paper, we’ll focus on the first one, the introduction of CoV-2 into North America
Before we get there, important points abt cov-2 genome:
1. As a cov, large relative to RNA viruses (~30k bp)
2. #1 possible because of a high fidelity proofreading exoribonuclease
3. Because of #2, v slow rate of evolution (evolutionary rate much slower than transmission rate)
Back to the paper. They used sampling from simulations to show that observed pattern of observed viruses through March 15 would be extremely unlikely if descended from WA1
They further bolstered this claim by looking at more exhaustive collection of genomes in Washington area, finding a later virus that lacked two washington outbreak clade-defining mutations and showing that again unlikely to descend from WA1
They then proceed to a bayesian phylogeographic analysis suggestion this phylogeny accounting for gaps in the data, placing the initial introduction from which the washington outbreak clade descended around Feb 1.
They do a number of other analyses to generate this projection of early introductions into Europe and the US. Key pt: multiple “dead end” intros prior to establishment, highlighting narrow opportunity for contact tracing / case finding to prevent this
Next, updates on
- pathogenesis
- immunity
- re-infection
We presented this model on 3/25 based on what was known at that time. Even at that time a lot was known about the illness course. In general, it involves a complex interplay between the virus and the immune system
This small study compared 3 cytokines from patients with critical COVID to other patients needing ICU level with non-cytokine storm states and found cytokine levels were lower among the patients with COVID.
-->Critical COVID may not be a cytokine storm

jamanetwork.com/journals/jama/…
There is now stronger evidence that viral load is associated with mortality and severe COVID-19 outcomes. This is from a NYC cohort with 678 patients
academic.oup.com/cid/advance-ar…
Another NYC cohort of nearly 1200 patients with similar findings thelancet.com/journals/lanre…
Recent paper from Cancer Cell looking at more than 3000 patients with COVID-19 also from NYC and similarly found a strong association between high viral load and severe outcomes
sciencedirect.com/science/articl…
In a multivariable model they found some factors associated with higher viral loads, including age and baseline inhaled, nasal, or oral corticosteroids.
Moving on to an important update in the adaptive immune response to COVID-19. The group presenting this next paper has already done important COVID-19 work. Here Dr. Fauci holding an earlier paper we have discussed
cell.com/cell/pdf/S0092…
In their new paper, this research team classifies broad adaptive immune responses to COVID-19. First, they look at RBD antibodies and find IgG and IgA are frequently present, but IgM less so
cell.com/cell/pdf/S0092…
They find receptor binding domain (RBD) IgG titers correlate with Spike IgG and neutralizing antibody titers
They look at specific CD4 and CD8 cell responses to SARS-CoV-2 and fine these are common in convalescent patients but less common in acute patients
They then look at adaptive immune responses and disease severity and find: no association for neutralizing Abs. Stronger specific CD4, CD8 and composite adaptive immune responses are associated with more mild outcomes
That age is associated with severe outcomes has been found around the globe. They report this in their cohort. They find that naive CD4 and CD8 cell percentage declines with age and that naive CD8 cell percentage is associated with severe disease for acute and convalescent cases
They conclude that a coordinated adaptive immune response and not just an antibody response seem to be needed to limit disease severity. Immunologic changes with age may at least partially explain severity spectrum
We propose updating the model for pathogenesis as in this slide. In mild cases a modest viral load is associated with robust coordinated adaptive immune response. Severe cases are marked by much higher viral loads with an uncoordinated response
This paper looks at reinfection in other common covs. Researchers use a cohort with years samples and look at reinfections in 10 patients, defining reinfection as increase in antibody titers of the 4 common coronaviruses. They find reinfections are common

doi.org/10.1038/s41591…
Reinfections are seen as early as 6 months and are common by 12 months.
A seasonality in incidence of new coronavirus infections was seen. This is predicted eventually once SARS-CoV-2 has circulated widely enough
Hong Kong case was first credible cov2 reinfection case
Many other cases need more details. Perplexing that some are reporting possible worse symptoms at reinfection (immune protection from prior episode might be expected)
academic.oup.com/cid/advance-ar…
A summary slide of the papers we covered here
Slide deck here: docs.google.com/presentation/d…
Again, video here:
hopeconference.net/conferences/fi…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Aaron Richterman, MD

Aaron Richterman, MD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AaronRichterman

May 31, 2023
Over 100 governments in low- and middle-income countries have introduced anti-poverty cash transfer programs over the last 3 decades

In new research, we examined the effects of these initiatives on the ultimate health outcome — mortality

Published today in @Nature /1 Image
We used >80 national surveys in 37 low- and middle-income countries to create longitudinal survival datasets for 4 million adults & 3 million children 2000-2019

About 1/2 the countries started cash transfer programs, & 1/2 the programs were unconditional (no strings attached) /2 Image
We used difference-in-difference models to show these programs led to a 20% reduction in mortality for women, and an 8% reduction in risk of death for children under 5
/3 Image
Read 8 tweets
Nov 16, 2021
New pre-print from @EricMeyerowitz and me reviewing loads of new Delta transmission data.

One area we cover — updates on vaccines' effects on transmission in the Delta era 🧵 1/24

papers.ssrn.com/sol3/papers.cf…
First, to review, vaccines can provide:
-direct protection (reduction in infx/disease among vaccinated ppl)
-indirect protection (reduction in infection among all community members through ⬇️ transmission)
/2

nature.com/articles/s4157…
Indirect protection can be generated by
1) ⬇️ risk of infection (if person not infected, cannot transmit)
2) ⬇️ infectiousness of vaccinated person w infection

Prior to delta, 1) + 2) = substantial transmission reduction of 75%+. Our pre-delta review:
/3

academic.oup.com/ofid/advance-a…
Read 24 tweets
Aug 24, 2021
As @mugecevik points out, despite the recent proliferation of vaccine studies using routinely collected testing data, the majority of these cannot be reliably be used to estimate VE vs all infections because they do not use systematic testing and/or control for confounding.
Vaccine protection against all infections is one important way (of several) that vaccines reduce transmission (discussed👇). Here is an updated table of high-quality studies assessing VE against infection, including just 3 from the delta era at the bottom
academic.oup.com/ofid/advance-a…
When using regular (or cross-sectional) systematic testing to estimate VE, you are really measuring VE against a composite of infection and duration of PCR-positivity, as highlighted recently by @dylanhmorris.
Fascinating discussion of these methods here sciencedirect.com/science/articl…
Read 4 tweets
Aug 11, 2021
This 👇claim arises principally from Israeli data (which is unpublished in any form so will withhold judgment) and from the UK REACT 1 study, rounds 12 & 13. But... is the REACT 1 data likely to be solely explained by delta? 🧵
(study link spiral.imperial.ac.uk/handle/10044/1…)
This is the table in question. You can see VE of a combination of AZ/MRNA vs symptomatic infection was 83% (19-97%) in round 12, but only 59% (23-78%) in round 13. The concern of course is that this drop in VE is due to delta, which had completely taken over by round 13 /2
However, while 100% of the isolates identified in round 13 were delta, 80% in round 12 were also delta (20% were alpha). Any effect of delta on VE should have been partially seen in round 12. /3
Read 7 tweets
Jul 31, 2021
The question at hand: what is the relative transmission potential of a vaccinated person who becomes infected with delta? This 👇new report from Singapore is much more informative on this question than the CT data released so far from Ptown and Wisconsin.
medrxiv.org/content/10.110…
First, importantly, reducing transmission potential of a person who becomes infected is only one component on the transmission reduction effect of the vaccines. The other: reducing the likelihood of becoming infected in the first place. We discuss here👇
academic.oup.com/ofid/advance-a…
We still await definitive evidence from systematic sampling on the ? of overall infection risk reduction with vaccination, but w strong protection vs symptomatic disease, expect that there will still be substantial protection (50+%) vs overall infection
nejm.org/doi/full/10.10…
Read 10 tweets
Jan 12, 2021
Interesting poll. Selection/response bias aside, majority picked a low probability, but 40% still thought there was 10+% prob that vaccines will not substantially prevent transmission. This is why I have become convinced this concern is highly unlikely (borderline implausible) 🧵
1. Data from screening PCR at the time of the 2nd moderna mrna vaccine, showing reductions in asymptomatic PCR positivity. This is before the 2nd dose and if anything will underestimate effect. Will have additional confirmation from unblinding pcr and ab

2. Data from AZ vaccine chadox study is a mess, but they did weekly PCR screening and points in the same direction.
thelancet.com/action/showPdf… Image
Read 27 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(